Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Background:
Mitochondrial disease is a rare disorder. It can cause poor growth, developmental delays,
muscle weakness, and other symptoms. The disease is usually inherited. It can be present at
birth or develop later in life. Infection is a major cause of disease and death in people
with this disease. Researchers want to learn more about how infection and the declining
health of people who have this disease may be related to the COVID-19 pandemic. To do this,
researchers will study the DNA of people who become ill with suspected or confirmed
coronavirus. Their DNA will be compared to the DNA of their family members.
Objective:
To learn more about how genes may play a role in how COVID-19 affects people with
mitochondrial disease.
Eligibility:
People age 2 months and older with mitochondrial disease and a suspected or confirmed
diagnosis of COVID-19.
Description: To identify immune signatures that associate with host responses todisease that would allow improved patient stratification and identification of potential therapeutic targets to mitigate the severesymptoms and sequelae of infection in mitochondrial disease.
Measure: We will perform whole blood transcriptomic analysis, humoral response profiling and soluble mediator profiling. Time: Undefined for natural history studyDescription: to stratify severity of illness based on clinical factors (e.g. intensive care status, ventilatory support, clinical laboratory data, radiologyrecords)
Measure: Patient Medical Records for Data Abstraction Time: Undefined for natural history studyDescription: to understand functional status, healthcare resource access and other sociodynamic factors as they affect the mitochondrial disease community.
Measure: Patient centered outcomes data via questionnaires Time: Undefined for natural history study